Yes, the Phase 1 results reported were great. Dramatic reduction in free serum alpha-synuclein along with a very good safety profile (well tolerated) with just one dose. Of course, we still need to see if a reduction in a-syn will actually lead to a slowing, stopping or reversal of the disease. That won't be known until they report some interim results from the ongoing phase 2 study.

http://ir.prothena.com/releasedetail...leaseID=902569